S. Fuerst-Recktenwald

发表

Ethnic origin is unrelated to autoimmunity and residual pancreatic function in 471 youth with clinically diagnosed type 2 diabetes

T. Danne, M. Gottschalk, S. Fuerst-Recktenwald, 2009, Pediatric diabetes.

Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States

R. Finkel, S. Guye, B. Darras, 2022, Muscle & nerve.

Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial

G. Comi, E. Mercuri, F. Muntoni, 2020, Neuromuscular Disorders.

Safety, efficacy and weight effect of two 11β‐HSD1 inhibitors in metformin‐treated patients with type 2 diabetes

T. Heise, C. Kapitza, L. Morrow, 2014, Diabetes, obesity & metabolism.

Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

G. Comi, S. Corti, E. Mazzone, 2022, The Lancet Neurology.

Oral administration of the 11β-hydroxysteroid-dehydrogenase type 1 inhibitor RO5093151 to patients with glaucoma: an adaptive, randomised, placebo-controlled clinical study

D. Hainzl, W. C. Stewart, D. Schwab, 2017, BMJ Open Ophthalmology.

Points to Consider when Planning the Collection of Blood or Tissue Samples in Clinical Trials of Investigational Medicinal Products in Children, Infants and Neonates

M. Turner, D. Hawcutt, Tony Nunn, 2010 .

SUNFISH Part 2: Efficacy and Safety of Risdiplam (RG7916) in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy (SMA) (1260)

E. Mazzone, A. Kostera-Pruszczyk, K. Gorni, 2020, Neurology.